Drug intelligence / Profile preview

OCU-310

Development stage: Unknown
Lead developer: Ocugen
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

OCU-310 is an investigational ophthalmic nanoemulsion of brimonidine tartrate (0.2%) developed by Ocugen for the treatment of dry eye disease (DED). Utilizing the proprietary OcuNanoE technology platform, OCU-310 is formulated as a preservative-free eye drop designed to improve the signs and symptoms of DED while enhancing tolerability. Brimonidine tartrate acts as a selective alpha-2 adrenergic receptor agonist, a mechanism traditionally used in glaucoma management but repurposed here to address ocular surface inflammation and redness associated with dry eye. The drug has undergone Phase 3 clinical evaluation, where its efficacy was measured using the Symptom Assessment in Dry Eye (SANDE) score and lissamine green conjunctival staining.

Other names: brimonidine tartrate 0.2% nanoemulsion

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on OCU-310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCU-310.